Dudley & Shanley Inc. Makes New $3.97 Million Investment in Pfizer Inc. $PFE

Key Points

• Dudley & Shanley acquired 165,000 Pfizer shares during the second quarter, valued at approximately $3.97 million. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Pfizer exceeded quarterly expectations, reporting adjusted EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus $14.40 billion expected. The company issued fiscal 2026 EPS guidance of $2.80–$3.00.
• Pfizer’s $0.43 quarterly dividend implies a 6.4% annualized yield, but analysts remain cautious, with an overall “Hold” rating and an average price target of $28.28 amid patent-expiration concerns and weak COVID-product sales.

Dudley & Shanley Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 165,000 shares of the biopharmaceutical company's stock, valued at approximately $3,973,000.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter valued at about $26,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 427 shares during the period. Evolution Wealth Management Inc. lifted its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 566 shares during the period. Abound Financial LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $31,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter valued at approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.70 on Monday. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The stock has a fifty day moving average of $25.02 and a 200-day moving average of $26.17. The company has a market capitalization of $152.20 billion, a PE ratio of 35.14 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm posted $0.78 EPS. The company's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.97 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 29th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. UBS Group reissued a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. BMO Capital Markets cut their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Pfizer in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $28.28.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Better-than-expected Q2 results supported the stock. Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate and revenue of $15.03 billion versus expectations of $14.40 billion. The company also raised its 2026 revenue outlook, helping offset concerns about declining COVID-related sales. Pfizer Inc. Q2 2026 Earnings Call Summary
• Positive Sentiment: Pipeline progress is improving Pfizer’s longer-term outlook. Analysts highlighted the company’s broader pipeline, including the potential obesity treatment berobenatide and PF-07328948. Berobenatide is being compared with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, although Pfizer still faces significant development and competitive hurdles. Pfizer’s Next Weight-Loss Weapon
• Positive Sentiment: Pfizer and BioNTech advanced COVID-19 vaccine studies. A new Phase 4 study of a variant-adapted booster, along with progress on a next-generation pediatric booster, could support future vaccine demand and preserve the partnership’s commercial position. Variant-Adapted COVID-19 Booster Study
• Neutral Sentiment: Analyst opinion remains mixed. Some analysts are bullish after the earnings beat and pipeline updates, while RBC Capital maintained a Hold rating, indicating that valuation and execution risks continue to limit conviction. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: Patent expirations and obesity-program uncertainty remain overhangs. Investors are questioning whether Pfizer’s pipeline can replace revenue lost to upcoming patent cliffs, while previous obesity setbacks make the berobenatide opportunity particularly important but far from assured. Pfizer’s Patent and Pipeline Outlook
• Negative Sentiment: COVID product sales remain weak. Pfizer’s COVID pill revenue reportedly fell 95%, underscoring the company’s continuing dependence on non-COVID products and pipeline launches to drive growth. Pfizer COVID Pill Revenue Decline

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source